Molecular mechanisms linking diabetes mellitus and Alzheimer disease: beta-amyloidpeptide, insulin signaling, and neuronal function
- 24 March 2011
- journal article
- review article
- Published by Oxford University Press (OUP) in Molecular BioSystems
- Vol. 7 (6) , 1822-1827
Abstract
The incidence of Alzheimer disease (AD) and diabetes mellitus (DM) is increasing at an alarming rate and has become a major public health concern worldwide. Recent epidemiological studies have provided direct evidence that DM is a strong risk factor for AD; this finding is now attracting attention. However, the underlying mechanisms for this association remain largely unknown. Previous in vitro and in vivo studies reported that diabetic conditions could cause an increase in the beta-amyloid peptide (Aβ) levels, which exhibits neurotoxic properties and plays a causative role in AD. However, unexpectedly, recent clinicopathological studies have shown no evidence that the pathological hallmarks of AD, including amyloid plaque, were increased in the brains of diabetic patients, suggesting that DM could affect the pathogenesis of AD through mechanisms other than modulation of Aβ metabolism. One possible mechanism is the alteration in brain insulin signaling. It has been shown that insulin signaling is involved in a variety of neuronal functions, and that it also plays a significant role in the pathophysiology of AD. Thus, the modification of neuronal insulin signaling by diabetic conditions may contribute to AD progression. Another possible mechanism is cerebrovascular alteration, a common pathological change observed in both diseases. Accumulating evidence has suggested the importance of Aβ-induced cerebrovascular dysfunction in AD, and indicated that pathological interactions between the receptor for advanced glycation end products (RAGE) and Aβ peptides may play a role in this dysfunction. Our study has provided a further understanding of the potential underlying mechanisms linking DM and AD by establishing novel mouse models showing pathological manifestations of both diseases. The current review summarizes the results from recent studies on the pathological relationship between DM and AD while focusing on brain insulin signaling and cerebrovascular alteration. It also discusses the therapeutic potential of these findings and future treatment strategies for AD.Keywords
This publication has 57 references indexed in Scilit:
- The overlap between neurodegenerative and vascular factors in the pathogenesis of dementiaActa Neuropathologica, 2010
- Molecular Interplay between Mammalian Target of Rapamycin (mTOR), Amyloid-β, and TauJournal of Biological Chemistry, 2010
- Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Aβ deposition in an Alzheimer mouse model with diabetesProceedings of the National Academy of Sciences, 2010
- Glycogen synthase kinase 3: more than a namesakeBritish Journal of Pharmacology, 2009
- Inhibition and Modulation of γ-Secretase for Alzheimer's DiseaseNeurotherapeutics, 2008
- Insulin Receptor Signaling Regulates Synapse Number, Dendritic Plasticity, and Circuit Function In VivoNeuron, 2008
- Abdominal obesity and metabolic syndromeNature, 2006
- RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brainNature Medicine, 2003
- RAGE and amyloid-β peptide neurotoxicity in Alzheimer's diseaseNature, 1996
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991